NDA 012151 · Pfizer
Aldactone
Spironolactone · Oral · Aldosterone Antagonist
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Nov 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1960
Jan 21, 1960
Approved uses
2
Original approval plus efficacy supplements
Registered trials
286
52 Phase 3, 28 recruiting
FAERS reports
142,744
111,491 serious, 18,312 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 30, 1981 Supplement 30 · Efficacy
- Jan 21, 1960 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
- ALDACTONE · SPIRONOLACTONE 25MG · TABLET, ORAL · Prescription · TE AB
- ALDACTONE · SPIRONOLACTONE 50MG · TABLET, ORAL · Prescription · TE AB
- ALDACTONE · SPIRONOLACTONE 100MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Spironolactone" as an intervention, any sponsor and status, largest first.
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Effect of MRA on Cardiovascular Disease in Patients With Hypertension and HyperaldosteronemiaPivotal-lookingEnrolling by invitation
Nanfang LiAcademic, hospital or other
NCT05688579 · 8,000 participants (planned) · Start Apr 16, 2023 · Primary completion Dec 31, 2026
Drug: Mineralocorticoid Receptor Antagonists(MRAs) · For: Hypertension; Hyperaldosteronaemia
Sites: Ürümqi, China
- Colchicine and Spironolactone in Patients with MI / SYNERGY Stent RegistryPivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT03048825 · 7,264 participants · Start Feb 1, 2018 · Primary completion Aug 9, 2024
Drug: Colchicine; Spironolactone and 2 more · For: ST Elevation Myocardial Infarction; Non ST Elevation Myocardial Infarction
Sites: Bakersfield, California; Washington D.C., District of Columbia; Chicago, Illinois · 109 sites in all
- A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart FailurePivotal-lookingEnrolling by invitation
Bispebjerg HospitalAcademic, hospital or other
NCT03984591 · 7,200 participants (planned) · Start Nov 1, 2020 · Primary completion Dec 31, 2028
Drug: Eplerenone; Spironolactone · For: Systolic Heart Failure
Sites: Copenhagen, Denmark
- Recurrent Stroke Prevention Clinical Outcome StudyPivotal-lookingStatus unknown
Biomedis International Ltd.Academic, hospital or other
NCT01198496 · 5,000 participants (planned) · Start Oct 2010 · Primary completion Dec 2017
Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone · For: Hypertension; Stroke; Blood Pressure
Sites: Shimotsuke, Japan
- Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac DeathPivotal-lookingTerminated
Unity Health TorontoAcademic, hospital or other
NCT00524862 · 5,000 participants (planned) · Start Oct 2007 · Primary completion Apr 2011
Drug: Optimized medical therapy · For: Coronary Heart Disease; Congestive Heart Failure; Ventricular Dysfunction and 2 more
Sites: Hamilton, Canada; Kingston, Canada; London, Canada · 10 sites in all
- Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic FunctionPivotal-lookingCompleted
Carelon ResearchAcademic, hospital or other
NCT00094302 · 3,445 participants · Start Aug 2006 · Primary completion Jun 2013
Drug: Spironolactone; Placebo · For: Cardiovascular Diseases; Heart Diseases; Heart Failure, Congestive
Sites: Birmingham, Alabama; Glendale, Arizona; Phoenix, Arizona · 270 sites in all
- Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and ApplicationPivotal-lookingNot yet recruiting
Tibet Autonomous Region People's HospitalAcademic, hospital or other
NCT07639931 · 3,035 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 20, 2028
Drug: Multicenter study of HAPE group:NO Group · For: Severe High Altitude Pulmonary Edema; Severe High Altitude Cerebral Edema
Sites: Lhasa, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea11,078
- fatigue8,762
- nausea8,345
- diarrhoea8,003
- acute kidney injury7,153
- dizziness6,673
- headache6,414
- hypotension6,175
- off label use6,086
- drug ineffective5,550
- fall5,362
- asthenia5,282
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,611 |
| 2005 | 1,925 |
| 2006 | 1,911 |
| 2007 | 1,861 |
| 2008 | 2,088 |
| 2009 | 2,528 |
| 2010 | 3,341 |
| 2011 | 3,581 |
| 2012 | 4,304 |
| 2013 | 3,937 |
| 2014 | 5,469 |
| 2015 | 7,144 |
| 2016 | 8,776 |
| 2017 | 8,042 |
| 2018 | 9,684 |
| 2019 | 9,988 |
| 2020 | 9,246 |
| 2021 | 8,774 |
| 2022 | 8,916 |
| 2023 | 9,822 |
| 2024 | 10,781 |
| 2025 | 10,709 |
| 2026 | 8,302 |
Recalls
1 FDA enforcement reports for this application.
Sep 4, 2013 · Class II · Terminated
Marketed without an Approved NDA/ANDA: This recall is being initiated because of changes to the dissolution profile in distributed lots resulting from a manufacturing site change. There is currently no approved...
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Aldactone (Spironolactone)
2024 spending
$429K
Beneficiaries
469
1,291 claims
Per beneficiary
$914
$3.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $591,299 |
| 2021 | $624,111 |
| 2022 | $535,855 |
| 2023 | $545,668 |
| 2024 | $428,587 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial.
Lee CJ, Ihm SH, Shin DH, et al. · JAMA 2025 · Clinical Trial, Phase IV, Comparative Study
- Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials.
Zhao JV, Xu L, Lin SL, et al. · J Am Soc Hypertens 2016 · Meta-Analysis, Systematic Review
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Williams B, MacDonald TM, Morant S, et al. · Lancet 2015 · Comparative Study, Randomized Controlled Trial
- Spironolactone for heart failure with preserved ejection fraction.
Pitt B, Pfeffer MA, Assmann SF, et al. · N Engl J Med 2014 · Multicenter Study, Randomized Controlled Trial
- The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Pitt B, Zannad F, Remme WJ, et al. · N Engl J Med 1999 · Clinical Trial, Multicenter Study
- Routine Spironolactone in Acute Myocardial Infarction.
Jolly SS, d'Entremont MA, Pitt B, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.